Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections.
Neuron. 2014-11-01; 84(4): 697-707
DOI: 10.1016/j.neuron.2014.10.011
Lire sur PubMed
1. Neuron. 2014 Nov 19;84(4):697-707. doi: 10.1016/j.neuron.2014.10.011. Epub 2014
Nov 6.
Direct targeted quantitative molecular imaging of neurotransmitters in brain
tissue sections.
Shariatgorji M(1), Nilsson A(1), Goodwin RJ(2), Källback P(1), Schintu N(3),
Zhang X(3), Crossman AR(4), Bezard E(5), Svenningsson P(3), Andren PE(6).
Author information:
(1)Biomolecular Imaging and Proteomics, National Center for Mass Spectrometry
Imaging, Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box
591 BMC, 75124 Uppsala, Sweden.
(2)Biomolecular Imaging and Proteomics, National Center for Mass Spectrometry
Imaging, Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box
591 BMC, 75124 Uppsala, Sweden; AstraZeneca R&D, Alderley Park, Macclesfield,
Cheshire SK10 4TF, UK.
(3)Center for Molecular Medicine, Department of Neurology and Clinical
Neuroscience, Karolinska Institutet and Karolinska University Hospital, 17176
Stockholm, Sweden.
(4)Faculty of Life Sciences, University of Manchester, Manchester M13 9PL, UK.
(5)Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293
Bordeaux, France.
(6)Biomolecular Imaging and Proteomics, National Center for Mass Spectrometry
Imaging, Department of Pharmaceutical Biosciences, Uppsala University, P.O. Box
591 BMC, 75124 Uppsala, Sweden. Electronic address: .
Current neuroimaging techniques have very limited abilities to directly identify
and quantify neurotransmitters from brain sections. We have developed a
molecular-specific approach for the simultaneous imaging and quantitation of
multiple neurotransmitters, precursors, and metabolites, such as tyrosine,
tryptamine, tyramine, phenethylamine, dopamine, 3-methoxytyramine, serotonin,
GABA, glutamate, acetylcholine, and L-alpha-glycerylphosphorylcholine, in
histological tissue sections at high spatial resolutions. The method is employed
to directly measure changes in the absolute and relative levels of
neurotransmitters in specific brain structures in animal disease models and in
response to drug treatments, demonstrating the power of mass spectrometry imaging
in neuroscience.
Copyright © 2014 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.neuron.2014.10.011
PMID: 25453841 [Indexed for MEDLINE]